SeaStar Medical Q1 revenue rises on QUELIMMUNE growth

SeaStar Medical Holding

13/05/2026 21:14

Overview

U.S. AKI therapy maker's Q1 revenue rose 69% yr/yr on expanded QUELIMMUNE adoption

Company posted Q1 net loss of $3.5 mln, with loss per share at $0.90

Advanced enrollment in pivotal NEUTRALIZE-AKI trial for adult AKI patients

Outlook

SeaStar Medical anticipates 2026 net product revenue of about $2 mln

Company expects to complete NEUTRALIZE-AKI trial enrollment by end-2026 and begin PMA submission

SeaStar Medical aims to broaden QUELIMMUNE adoption to 15 more top-ranked children's hospitals in 2026

Result Drivers

EXPANDED CUSTOMER BASE - Co added 7 top-rated children’s hospitals for QUELIMMUNE pediatric AKI therapy, increasing customer base to 17 and driving higher Q1 revenue

CLINICAL TRIAL ENROLLMENT - Co advanced enrollment in NEUTRALIZE-AKI pivotal trial for adult AKI, activating multiple new clinical sites and enrolling 198 of 339 patients

RESEARCH EXPENSES - Decrease in research and development expenses mainly due to lower clinical trial costs for NEUTRALIZE-AKI, offset by higher personnel and external service costs

Company press release: ID:nGNXvGRyP

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.90
Q1 Net Income
-$3.52 mln
Q1 Operating Expenses
$4.05 mln
Q1 Operating Income
-$3.60 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for SeaStar Medical Holding Corp is $9.00, about 86% above its May 12 closing price of $4.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)